MX2022012535A - Composiciones y usos de polimeros de aminoacidos sinteticos aplicados localmente para la prevencion y tratamiento de infecciones virales. - Google Patents

Composiciones y usos de polimeros de aminoacidos sinteticos aplicados localmente para la prevencion y tratamiento de infecciones virales.

Info

Publication number
MX2022012535A
MX2022012535A MX2022012535A MX2022012535A MX2022012535A MX 2022012535 A MX2022012535 A MX 2022012535A MX 2022012535 A MX2022012535 A MX 2022012535A MX 2022012535 A MX2022012535 A MX 2022012535A MX 2022012535 A MX2022012535 A MX 2022012535A
Authority
MX
Mexico
Prior art keywords
viral infections
compositions
prevention
treatment
amino acid
Prior art date
Application number
MX2022012535A
Other languages
English (en)
Inventor
Michael P Bevilacqua
Daniel J Huang
Original Assignee
Amicrobe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicrobe Inc filed Critical Amicrobe Inc
Publication of MX2022012535A publication Critical patent/MX2022012535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas antimicrobianas que contienen antimicrobianos catiónicos y métodos para usarlos para prevenir y/o tratar infecciones virales.
MX2022012535A 2020-04-08 2021-04-06 Composiciones y usos de polimeros de aminoacidos sinteticos aplicados localmente para la prevencion y tratamiento de infecciones virales. MX2022012535A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007295P 2020-04-08 2020-04-08
US202063066294P 2020-08-16 2020-08-16
PCT/US2021/025925 WO2021207164A1 (en) 2020-04-08 2021-04-06 Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections

Publications (1)

Publication Number Publication Date
MX2022012535A true MX2022012535A (es) 2022-12-13

Family

ID=78023436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012535A MX2022012535A (es) 2020-04-08 2021-04-06 Composiciones y usos de polimeros de aminoacidos sinteticos aplicados localmente para la prevencion y tratamiento de infecciones virales.

Country Status (9)

Country Link
US (1) US20230149333A1 (es)
EP (1) EP4132468A4 (es)
JP (1) JP2023521796A (es)
KR (1) KR20220166832A (es)
AU (1) AU2021252544A1 (es)
BR (1) BR112022020450A2 (es)
CA (1) CA3179706A1 (es)
MX (1) MX2022012535A (es)
WO (1) WO2021207164A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718003C (en) * 2008-03-10 2016-05-03 The University Of Tokyo Copolymer including uncharged hydrophilic block and cationic polyamino acid block having hydrophobic group in part of side chains, and use thereof
JP5902171B2 (ja) * 2010-08-23 2016-04-13 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 高抗微生物活性および低毒性を有する材料の組成物および使用
KR102141254B1 (ko) * 2012-03-23 2020-08-04 아미크로베, 인코포레이티드. 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도
CN110740744A (zh) * 2017-04-06 2020-01-31 艾麦克罗比公司 性能和安全性增强的局部施用的抗微生物剂的组合物和应用

Also Published As

Publication number Publication date
JP2023521796A (ja) 2023-05-25
US20230149333A1 (en) 2023-05-18
BR112022020450A2 (pt) 2022-12-20
EP4132468A4 (en) 2024-04-17
EP4132468A1 (en) 2023-02-15
CA3179706A1 (en) 2021-10-14
KR20220166832A (ko) 2022-12-19
AU2021252544A1 (en) 2022-11-03
WO2021207164A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CR20230404A (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2022014925A (es) Moduladores de il-17a.
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112022013480A2 (pt) Métodos de tratamento de coronavírus
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
SG11202112796YA (en) N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
MX2022012535A (es) Composiciones y usos de polimeros de aminoacidos sinteticos aplicados localmente para la prevencion y tratamiento de infecciones virales.
MX2023009613A (es) Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2022011596A (es) Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112021019884A2 (pt) Método de tratamento e prevenção de infecções ósseas e articulares
BR112020024261B8 (pt) Composto de fórmula (ia) e composição farmacêutica
PH12018502568A1 (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
MX2023011328A (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos.
EA201992234A1 (ru) Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.